GS GSK GSK plc Loading... : Bullish and Bearish Analyst Opinions

GSK halted development of an experimental drug for chronic cough, citing it was unlikely to transform patient care.

GSK shares declined after the company discontinued its chronic cough treatment, but no forward-looking position is stated.

GSK co-mentioned negatively alongside camlipixant discontinuation; no explicit directional commitment from speaker.

GSK reports Calm-1 met primary endpoint with camlipixant but Calm-2 failed to achieve statistical significance on the same primary endpoint.

Jefferies resumes coverage of GSK with a Buy rating and a target price of 2,500 pence.

GSK and Hansoh Pharmaceutical's experimental drug shows improved survival in small-cell lung cancer patients in a late-stage Chinese trial.

GSK announces that its ARTEMIS-8 Phase III study met the primary endpoint in advanced or relapsed small-cell lung cancer.

Observes a positive signal from GSK's new CEO cancer deal, but no personal directional commitment or trade thesis.

GSK CEO states the company does not need the Nuvalent deal to achieve its 40 billion pound sales target by 2031

European stock movers show SoftwareOne up 5.3 percent and Givaudan up 2.8 percent while AstraZeneca and GSK each fall 1.3 percent.

GSK is in discussions to acquire cancer drug developer Nuvalent for between 9 billion and 10 billion dollars according to the Financial Times.

Reports an M&A deal between NUVL and GSK valued >$9B; factual development with mild positive tone.

The Financial Times reports that a deal between GSK and Nuvalent is expected to be finalized as early as this week.

GSK is in talks to acquire cancer-focused biotech Nuvalent in a deal valued at more than nine billion dollars according to the Financial Times.

Seeking Alpha highlights Stephen Ayers' bearish view that Moderna's mRESVIA is struggling against entrenched rivals Pfizer and GSK, with waning efficacy and a limited market dimming its blockbuster potential.

Short GSK because the high level of competition in the pharmaceutical industry makes it statistically improbable for GSK to exclusively develop a cure for asthma, negating a potential source of future upside.

Reeves explicitly states they have "secured a deal around pharmaceuticals" with the US which is "crucial for the UK" and asserts these terms are "not affected by the Supreme Court ruling" or current diplomatic tensions. While the broader UK-US trade relationship faces headwinds due to the UK's refusal to join offensive military action against Iran, the pharmaceutical sector has been ring-fenced. This regulatory certainty provides a safe harbor for UK pharma giants compared to other export sectors that may face retaliatory tariffs or "uncertainty." Long UK Pharma majors as a defensive play against geopolitical volatility; they retain access to their most critical market (US) regardless of the political spat. Unexpected executive orders from the US administration specifically targeting UK imports despite prior agreements.